INTRODUCTION
The discovery of a small pool of latently infected cells that persist in HIV-infected individuals receiving suppressive antiretroviral therapy (ART) has considerably dampened the hope of eradicating HIV with ART alone [1] [2] [3] . This long-lived reservoir is often considered the major obstacle to achieving a cure for HIV and therapeutic strategies that could limit its size may be a prerequisite to achieving control of viral replication upon ART withdrawal, which is also called HIV remission [4, 5] . Current evidence suggests that ART instituted early during acute HIV infection (AHI) is key to containing HIV reservoir establishment, particularly in long-lived CD4 þ T cells, providing a basis for its critical role in achieving HIV remission [6 & ,7,8] . Indeed, a prime example is the case of the Mississippi child who started ART by 2 days of life for 18 months and subsequently was able to remain with low HIV reservoirs and virally suppressed for 27 months in the absence of ART [9, 10] . Similarly, the VISCONTI cohort of adults in France was treated within the first 2 months of infection and was able to control viremia without ART for more than 5 years [11 && ]. Through key published works, this review covers the timing and mechanisms of HIV reservoir establishment and the effects of early ART on the HIV reservoirs as well as future research directions.
The latent HIV reservoir is established early after infection
The mechanisms responsible for the establishment of HIV latency are not fully elucidated. Latently infected cells are rare in vivo and appear to arise when activated CD4 þ T cells, the major targets cells for HIV infection, become infected and survive long enough to revert back to a resting memory state, which is nonpermissive for viral gene expression [12] . An alternative model proposes that HIV latency is directly established in resting CD4 þ T cells, following interaction with dendritic cells and/or specific chemokines [13, 14] .
No matter how latently infected cells are generated, several lines of evidence clearly indicate that the latent reservoir is established early in infection, indicating that one or both of these mechanisms occur within the first few days or weeks after transmission. Indeed, initiation of ART as early as 10 days after the onset of symptoms of primary HIV infection (PHI) does not prevent the generation of latently infected carrying infectious HIV despite the successful control of plasma viremia shortly after institution of therapy [15 & ]. Studies in nonhuman primates (NHPs), which have the advantage of precisely defining the time and location of the reservoir establishment, have also demonstrated that lentiviruses seed their reservoir within a few days postinfection; large numbers of resting CD4 þ T cells carry integrated simian immunodeficiency virus (SIV), and simian human immunodeficiency virus DNA [16] can be detected at the earliest stage of infection. In line with these results, Whitney et al. [17 && ] recently demonstrated that treatment with ART 3 days post-SIV mac251 infection in rhesus macaques blocks the emergence of viral RNA and proviral DNA in peripheral blood but does not prevent the establishment of a viral reservoir in tissues. After discontinuation of ART following 24 weeks of fully suppressive therapy, virus rebounded in all animals [17 && ]. These data indicate that the viral reservoir could be seeded substantially earlier than previously assumed [5] . Another study in SIV mac239 -infected rhesus macaques showed that ART initiated prior to peak virus replication (day 12) significantly limits systemic virus dissemination and seeding of the reservoir in the peripheral blood and lymphoid tissues [18] . Notwithstanding the important information generated by these studies conducted in NHP, it is crucial to caution their application to HIV infection in humans as SIV and HIV may establish their reservoir in distinct cells and tissues, and with different efficiency and kinetics. For instance, resting CD4 þ T and myeloid cells are essentially resistant to HIV infection due to the restriction factor, Sterile alpha motif domaincontaining protein 1 and HD domain-containing protein 1 (SAMHD1) [19, [20] [21] [22] , a mechanism that is counteracted by the SIV protein vpx, which is absent in HIV-1. This suggests that SIV may be more prone to directly establishing latency in resting CD4 þ T cells and myeloid cells when compared with HIV. Moreover, the amount of virus used to efficiently infect NHPs is usually much higher than the ones that cause natural HIV transmission in humans and ART may not be as effective in NHPs as in HIVinfected patients. Therefore, the establishment of latent viral reservoir in humans and NHPs may differ in numerous ways, and further studies are warranted to demonstrate that these experimental models can be used to investigate the mechanisms responsible for the establishment and persistence of the longlived HIV reservoir in infected individuals.
Early antiretroviral therapy limits the size of the latent HIV reservoir
Although the reservoir is seeded very early in infection, the beneficial effect of starting ART during the first weeks or months after infection to reduce the size of the latent reservoir has been reported in numerous studies. Strain et al. [23 && ] reported that after 12 months of ART, replication-competent virus could not be detected in all patients who initiated treatment before seroconversion, nor in the majority of individuals who initiated ART in the first 6 months after seroconversion [23 && ]. These observations were confirmed in several studies indicating that HIV-infected individuals who start ART within the first few months of HIV infection display a reservoir of smaller magnitude compared with those who start later in infection [6 & 
,24
& -26 & ,27 && ]. Of note, the association between early ART initiation and a reduced size of the
KEY POINTS
HIV persistence is established early in AHI in long-lived memory CD4 þ T cells that are nonpermissive for viral gene expression, therefore, not eliminated by immune surveillance or ART.
ART instituted during AHI can reduce the HIV reservoir size to a greater extent than when treatment is given in chronic HIV. However, infection generally persists in memory CD4 þ T cells in most early treated individuals.
Recent data suggest that treatment in the earliest AHI stage (Fiebig I) may protect central memory CD4 þ T cells from infection and skew the distribution of latently infected cells to the shorter lived memory CD4 þ T cells as is the case in individuals who control HIV without ART (elite controllers and PTCs).
ART in AHI may be the first critical step in the path to achieve HIV remission by containing HIV reservoir seeding prior to instituting additional interventions to eliminate all latently infected cells.
Early ART and HIV reservoirs Ananworanich et al. & ], although the limited size of the initial pool of latently infected CD4 þ T cells has been proposed to be the most important factor contributing to a smaller size of the reservoir after several years of therapy. Archin et al. [6 & ] demonstrated that although the frequency of cells harboring replication-competent HIV declines after the first year of ART in most acutely infected patients, no further decay is noted when this frequency reaches very low levels (less than 0.5 cells per million). Therefore, a subset of latently infected cells may persist indefinitely, even in patients who have started ART during acute infection. The identification of the phenotype of these cells, in which HIV may persist for decades, is currently an area of intense investigation. Indeed, the composition of the reservoir (i.e., its distribution in distinct memory CD4 þ T cell subsets) may provide crucial information on the mechanisms of HIV persistence, and several recent studies indicate that early ART greatly influences this parameter.
Early antiretroviral therapy alters the distribution of the reservoir in CD4 R T-cell subsets
Resting memory CD4 þ T cells are the predominantly infected cells in virally suppressed patients. The use of a combination of markers expressed by memory CD4 þ T cells has led to the identification of three cellular reservoirs in which HIV persists after prolonged suppressive ART, namely central (T CM ), transitional (T TM ) and effector (T EM ) memory CD4 þ T cells [24 & ,30] ( Fig. 1 ). Because of their very distinct functional and phenotypic properties [31] , these three cellular reservoirs may support viral persistence through different mechanisms. For instance, the drastic differences in the activation status of T CM and T EM cells [24 & ,32] suggest that the former might represent an ideal reservoir for latent HIV, whereas the latter may be more prone to support residual levels of viral replication in the face of ART. The relative contribution of each subset to the pool of HIV-infected cells is highly variable between HIVinfected individuals [24 & ]. Several recent studies suggest that a relatively low infection frequency of T CM cells may be strongly associated with lack of disease progression in a variety of apparently unrelated clinical scenarios in untreated individuals. Long-term nonprogressors (LTNPs) display a low infection frequency of T CM cells, which is associated with an increased size of the T CM pool and a greater number of anti-gag CD8 þ T cells. Of note, T CM from HLAB27/B57 LTNPs are markedly less infected than T CM from individuals who do not bear these protective alleles [33] . In addition, in the recently described VISCONTI cohort of posttreatment controllers (PTCs), who initiated ART early in infection and naturally control HIV replication in the absence of ART, T CM contribute very minimally to the total HIV reservoir [11 && ]. Taken together, the relative protection of T CM cells in LTNPs and PTCs suggests that a T CM compartment devoid of HIV may be an important correlate of natural control of HIV replication.
Can early ART initiation reproduces this skewed distribution of the reservoir by protecting T CM cells from infection? Preliminary data generated on samples from the RV254 study, an AHI study conducted by the Thai Red Cross AIDS Research Center and the US Military HIV Research Program, indicate that very early ART efficiently protects all memory CD4 þ T-cell subsets from infection, including the long-lived T CM cells [7] . This is in agreement with other studies investigating the frequency of infection of distinct memory CD4 þ T-cell subsets in study participants who initiated ART early in infection [8,26 & ,27 && ]. Whether the T CM subset is more protected than the other subset by early ART is still unclear.
In addition to T CM , T TM and T EM cells, the recently described stem cell memory T cells, which share functional and self-renewal properties with T CM cells [34] , may represent an additional relevant reservoir for HIV [35] . Importantly, early ART may significantly reduce the contribution of this extremely long-lived subset to the overall HIV reservoir 
Clinical trials of early antiretroviral therapy and the HIV reservoirs
There are, so far, only a limited number of studies evaluating the impact of ART initiated in AHI on the HIV reservoirs. A major limitation is the difficulty in identifying people in AHI; this is a narrow window that spans the first 4 weeks of infection when the HIV IgG antibody response is not yet detected by standard assays [28, 36] . The diagnosis generally requires nucleic acid testing that is costly and not part of standard testing algorithms in most settings. Thus, studies of acutely treated individuals are usually small. The immediate initiation of ART is also challenging, and in many studies, ART is initiated weeks or months after AHI is identified. . These studies consistently demonstrated the superiority of early ART over late treatment in reducing the HIV reservoir size as defined by HIV DNA levels (total and integrated, 2-long terminal repeat (LTR) circles 2-LTR circles) and frequencies of resting CD4 þ T cells that are capable of producing replication-competent virus. Occurrence of low-level viremia measured by single-copy HIV RNA assay is also less with early ART [6 & ]. The frequency of infected cells in the gastrointestinal tract was evaluated in two studies that observed a statistically significant decline in HIV DNA after early ART [25 & ,41] . Studies comparing standard vs. regimens intensified with integrase and entry inhibitors did not show a superior effect of the latter regimen, but these studies are greatly underpowered [42 
FUTURE RESEARCH
Most of the studies that have demonstrated the ability of early ART at reducing the size of the latent reservoir have been conducted on cells isolated from peripheral blood. Little information is known on the establishment of the reservoir in tissues (particularly the major anatomical HIV reservoirs such as the gut and lymph nodes) at the earliest stage of infection. This limitation is obviously attributable to the Early ART and HIV reservoirs Ananworanich et al. difficulty in accessing these samples, but also to the lack of a sensitive, reproducible and flexible assay that can measure a few latently infected cells harboring replication-competent HIV. Alleviating this technical limitation would also allow a better understanding of the relative importance of each memory T-cell subset to HIV persistence, as well as the capacity of early ART at interfering with the establishment of latency in these discrete subsets of cells.
The persistence of infection in T CM after 10 years of ART in the study by Buzon et al. [27 && ] suggests that treatment within the first 6 months of infection is not early enough, but it remains unknown what the window of opportunity to intervene is before reaching the 'point of no return.' Theoretically, the earlier ART is initiated (i.e., Fiebig stages I and II) [28] , the higher should be the chance for HIV remission. However, the PTCs in the VISCONTI cohort were mainly those treated in Fiebig IV and V stages [11
&&
]. Understanding the precise timing of ART initiation that has the greatest impact on HIV reservoirs will require careful characterization of patients at time of ART initiation for their history of HIV exposure and virologic and serologic markers of HIV. A concerted effort to evaluate and identify AHI staging system that could predict outcomes relevant to HIV cure (e.g., HIV reservoir size) would be a major advancement. Additionally, there is a dearth of data on the HIVspecific immune responses following early ART. It is possible that such immune responses are blunted with rapid treatment and viral suppression, as evidenced by the higher proportion of early treated individuals who remain HIV seronegative compared with the later treatment initiators [44, 45] . Knowledge on the association between existing immune responses and HIV reservoirs after AHI treatment will inform future immune-based strategies to eliminate latently infected cells.
CONCLUSION
It is clear that early ART results in lower reservoir size which could delay the time to viral rebound when ART is interrupted, as has been demonstrated in the Mississippi child. However, reaching sustained HIV remission or cure will require not only reduction size of the HIV reservoir, but also, to modify the distribution of the replication-competent HIV reservoir in CD4 þ T cells and tissues. ART initiated during AHI, however, may be the first critical step in the path aimed at HIV remission or cure by limiting the HIV reservoir establishment prior to employing additional interventions to eliminate all cells capable of producing HIV. 
